Novo Nordisk has announced headline results from Semaglutide Treatment Effect in People with obesity (STEP) 1, a phase 3a trial in the STEP programme, which revealed the study met both primary endpoints. STEP 1 is a 68-week randomised, double-blind, multicentre, placebo-controlled weight management trial.
Twenty-nine leading international partners have joined forces to establish a research consortium Stratification of Obese Phenotypes to Optimize Future Obesity Therapy (SOPHIA) with the aim of improving risk assessment of comorbidities and treatment for people with obesity. Obesity complications are common, but predicting who will develop any of the 200 known complications of obesity is extremely difficult. Moreover, there are insufficient predictors for who will respond to obesity treatments.
Fractyl Laboratories has received approval from the FDA of an Investigational Device Exemption (IDE) to begin a pivotal study of Revita DMR in type 2 diabetes (T2D) patients treated with insulin. This landmark pivotal study, called Revita T2Di, is a prospective, randomised, double-blind, sham-controlled study enrolling 300 patients at up to 35 sites around the world, with approximately 25 sites in the US.
Laparoscopic banded sleeve gastrectomy (LBSG) appears to be significantly more effective than laparoscopic sleeve gastrectomy (LSG) in terms of weight loss in the midterm follow-up, according to researchers from Italy. The randomised study, ‘Banded Sleeve Gastrectomy Improves Weight Loss Compared to Nonbanded Sleeve: Midterm Results from a Prospective Randomized Study’, published in the Journal of Obesity, sought to compare LBSG and LSG over a four-year follow-up.
Ethicon has announced its continued support of guidelines from the Society for American Gastrointestinal and Endoscopic Surgeons (SAGES), which recommends the use of personal protective equipment (PPE) and smoke evacuation in the operating room during laparoscopic and open surgery.
The childhood obesity rate may increase 2.4% or 1.27 million children if school closures to prevent the spread of the coronavirus continue into December, according to the study, ‘Projecting the impact of COVID-19 pandemic on childhood obesity in the U.S.: A microsimulation model’, published in the Journal of Sport and Health Science.
Researchers from the Open University of Catalonia and the Universitat Pompeu Fabra Department of Communication, Barcelona, Spain respectively, have performed a study based on the assumption that advertising is one of the factors that contributes to the obesogenic environment.
Xeris Pharmaceuticals has announced positive findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycaemic episodes following bariatric surgery.
Researchers from the University of British Columbia, Canada, believe they have identified a gene that may prevent weight gain, after using a genetic database of more than 47,000 people in Estonia. The gene is linked to thinness and may play a role in resisting weight gain in these metabolically healthy thin people. Deleting the gene resulted in thinner flies and mice, and that the expression of it in the brain may be involved in regulating energy expenditure.
Boston University School of Medicine researchers have discovered that anti-obesity medications such as phentermine and topiramate, used individually or in combination, can significantly reduce weight regain in patients after Roux-en-Y gastric bypass surgery. The retrospective study paper, 'The Mitigating Effect of Phentermine and Topiramate on Weight Regain after Roux-en-Y Gastric Bypass Surgery', was published in Obesity.